asenapine
- Generic Name
- asenapine
- Brand Names
- Saphris, Secuado, Sycrest
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16ClNO
- CAS Number
- 65576-45-6
- Unique Ingredient Identifier
- JKZ19V908O
Overview
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Background
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Indication
适用于成人精神分裂症和双相情感障碍患者的治疗。
Associated Conditions
- Bipolar 1 Disorder
- Mixed manic depressive episode
- Schizophrenia
- Acute Manic episode
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.